BRCA1 and hypoparathyroidism-retardation-dysmorphism syndrome: This supports non-BRCA1/2 etiologies for HRD and suggests that identification of non-BRCA1/2 etiologies may provide relevant information for therapeutic selection and may thereby impact clinical prognosis.